Application of Dual-Energy Spectral Computed Tomography to Thoracic Oncology Imaging.

Computed tomography (CT) is an important imaging modality in evaluating thoracic malignancies. The clinical utility of dual-energy spectral computed tomography (DESCT) has recently been realized. DESCT allows for virtual monoenergetic or monochromatic imaging, virtual non-contrast or unenhanced imaging, iodine concentration measurement, and effective atomic number (Zeff map). The application of information gained using this technique in the field of thoracic oncology is important, and therefore many studies have been conducted to explore the use of DESCT in the evaluation and management of thoracic malignancies. Here we summarize and review recent DESCT studies on clinical applications related to thoracic oncology.

INTRODUCTION

Dual-energy spectral computed tomography (DESCT) has recently re-emerged as an advance in computed tomography (CT). It offers important new functional and specific information. Although the concept of dual-energy CT was initially developed in 1973 (1), this technique was underutilized for decades due to technical limitations and workflow issues (2). However, this technique has rapidly gained popularity after the development of a first-generation dual-source CT system in 2006, which can improve material differentiation by using two different X-ray energy spectra. Current DESCT acquisition methods comprise of dual tubes either with or without beam filtration, rapid voltage switching with a single tube, a dual-layer detector with a single tube, a single tube with a split filter, or a single tube with sequential dual scans (2).

DESCT can provide both material-nonspecific and material-specific energy-dependent information as follows (2): 1) virtual monoenergetic or monochromatic imaging (VMI), 2) virtual non-contrast or unenhanced imaging (VNC), 3) iodine concentration (IC) measurement, and 4) effective atomic number (Zeff map). Moreover, recent computing developments have led to a shortened reconstruction time using DESCT data. Because of these technical developments, the use of DESCT is rapidly increasing in routine clinical practice, and its clinical utility in the diagnosis, management, and evaluation of response to therapy in thoracic malignancies has expanded. Here we summarize and review recent studies of DESCT in its clinical applications related to thoracic oncology. In addition, Table 1 summarizes the clinical application of DESCT according to DESCT techniques.

Table 1

Summary of Clinical Application of DESCT according to DESCT Techniques

DESCT Technique	Clinical Application	Examples	References
VMI	Artifact and noise reduction	• Improved image quality by decreasing metal or beam-hardening artifacts	(5678910)
		• Improved visualization of soft tissue lesions by decreasing image noise and increasing SNR and CNR
	Contrast enhancement	• VMI with low energy increased detectability, visibility, and correct measurement of LNs and improved accuracy of diagnosing LN metastasis	(1112131415)
		• Detection of inconspicuous osteoblastic metastases of vertebra from lung cancers
		• VMI with high energy resulted in low attenuation and nodule volumes, while VMI with low energy resulted in higher attenuation and nodule volumes (possibility of over/under-estimation should be considered)
VNC	Evaluation of mediastinal LNs	• Moderate agreement between TNC and VNC in evaluation of CT attenuation of mediastinal LNs	(1617)
		• May underestimate calcification in SPN or mediastinal LNs in VNC compared to TNC
	Evaluation of intratumoral hemorrhage	• Intratumoral hemorrhage can be detected in patents with NSCLC treated with anti-angiogenic agents	(18)
	Virtual non-calcium reconstruction for diagnosing vertebral metastasis	• Effectively suppressed calcium in multi-level vertebra by replacing HU of voxels containing calcium with virtual HU value as similar as possible to expected HU without calcium contribution	(19)
	Evaluation of adrenal masses	• Identified adrenal adenomas with 91% sensitivity and 100% specificity based on typical imaging features (non-contrast attenuation < 10 HU)	(20)
IC measurement	Differentiation between malignant and benign lesions	• Different IC parameters between malignant and benign lung lesions	(2021), (2526272829303132)
		• Different IC parameters between LNs metastasis and benign LNs
		• Different IC parameters between different LN diameters (normal: < 10 mm; intermediate: ≥ 10 mm to < 15 mm; enlarged: ≥ 15 mm)
	Differentiation of tumors, subtypes, pathologic grades, and molecular subcategories of lung cancers	• Different IC parameters according to histologic subtypes and pathologic grades of lung cancers	(23), (28), (333435363738)
		• Significant negative correlation between IC parameters and pathological grades of NSCLC
		• Different IC parameters between pulmonary metastases from different primary origins
		• Different IC parameters between low-risk thymomas from other thymic tumors
	Treatment response evaluation with/without correlation with positron emission tomography-CT	• IC parameters evaluating therapeutic effects in lung cancers or mediastinal metastatic LNs	(39404142434445)
		• Correlation between IC parameters and metabolic uptake in PET-CT and association with tumor recurrence
	Parenchymal perfusion defects due to central lung cancers or PTE	• Significant decrease in IC of pulmonary perfusion defects induced by central lung cancer or PTE	(20), (46)
Effective atomic number (Zeff map)	Not clear, but may differentiate tumors	• Significantly greater Zeff was measured in benign thyroid nodules than in papillary carcinomas	(23), (474849)
		• Higher Zeff was exhibited in soft tissue sarcomas than in normal tissues
		• Lower minimum Zeff and normalized mean Zeff were statistically correlated with malignant lung tumors
		• Different Zeff between squamous cell cancer, adenocarcinoma, and neuroendocrine tumors

CNR = contrast-to-noise ratio, DESCT = dual-energy spectral computed tomography, HU = Hounsfield unit, IC = iodine concentration, LN = lymph node, NSCLC = non-small cell lung cancer, PET-CT = 18F-fluorodeoxyglucose positron emission tomography, PTE = pulmonary thromboembolism, SNR = signal-to-noise ratio, SPN = solitary pulmonary nodules, TNC = true non-enhanced imaging, VMI = virtual monoenergetic or monochromatic imaging, VNC = virtual non-contrast or unenhanced imaging

VMI

VMI can be synthesized using DESCT scans by decomposing two basis materials based on projection-based or image-based methods. With single-source DESCT, VMI datasets are obtained in the projection-based domain, because these imaging data are acquired at the same projection angle (3). Contrastingly, with the dual-source platform, approximately a 90° phase difference between high- and low-energy projections necessitates the image-space domain.

The projection-based material decomposition algorithm assumes that any attenuation coefficient can be described as a linear combination of the mass attenuation coefficient of two basis materials (4). The imaged-based algorithm expresses linear attenuation coefficients from high- and low-energy data as a linear combination of the mass attenuation coefficients of the two basis materials (3). VMI has the potential to improve the quality of conventional polychromatic CT images and provide quantitative measurements (5).

Artifact and Noise Reduction

VMI may improve image quality by decreasing metal or beam-hardening artifacts (5). However, the suitable energy level of VMI for each situation is different. Gyobu et al. (6) reported that metallic artifact significantly decreased in VMI at 100 keV or 140 keV and that VMI improved the detection of pulmonary nodules in a thoracic phantom study. Liu et al. (7) reported that VMI at 74 keV with a metal artifact reduction algorithm could improve image quality for the micro-coil localization of pulmonary nodules. VMI also reduced beam-hardening artifact due to contrast media and improved image quality, and the optimal thoracic CT evaluation was best achieved at 100 keV and 130 keV (Fig. 1) (8).

Fig. 1

Example of VMI for artifact reduction.

Chest CT of delayed enhancement, conventional polychromatic images, and VMI at energy levels of 70, 100, 130, and 200 keV in 70-year-old male with diffuse large B cell lymphoma. Enlarged lymph node involved by lymphoma is shown in right axillary area (arrows). On conventional polychromatic image, it is difficult to evaluate right axillary lymph node because of beam-hardening artifact caused by contrast medium in right subclavian vein. However, 100 keV and 130 keV VMI reduced beam-hardening artifact such that lymph node can be assessed. VMI = virtual monoenergetic or monochromatic imaging

In addition, VMI provides for improved visualization of soft tissue lesions by decreasing image noise and increasing the signal-to-noise ratio and contrast-to-noise ratio. Two recent studies demonstrated that VMI at 60 keV or 70 keV provided the best combination of subjective and objective image quality in the evaluation of lung cancer (910).

The results of these studies indicate that the most suitable energy level for each situation is different. Therefore, the energy level should be adjusted to control for the artifact or when evaluating lung nodules on CT scans. It is worth researching the best energy level for specific situations to streamline image reconstruction for each software. Alternatively, if radiologists prefer to upload VMI reconstructions to a picture archiving and communication system (PACS), the target energy level can be preset based on such studies.

Contrast Enhancement

The detection of hilar lymph nodes (LNs) is sometimes difficult when the enhancement of the pulmonary vessel is almost the same as that of the LN. However, VMI with low energy increased detectability, visibility, and correct measurement of the LNs can improve the accuracy of diagnosing LN metastasis. This is because VMI with low energy provides increased contrast enhancement of the pulmonary vessels even if the scan is not performed during the early enhancement phase (Fig. 2) (1112). A recent study proved that VMI at 40 keV performed at a delayed phase (60 seconds after contrast media administration) was useful for the evaluation of hilar LNs, showing the greatest contrast differences between the pulmonary vessels and LNs (13).

Fig. 2

Example of VMI for evaluation of lymph node metastasis.

Chest CT images from 71-year-old male with lung cancer with mediastinal and bilateral hilar/interlobar lymph node metastases. In conventional polychromatic image, right interlobar lymph node detection is difficult because enhancement of pulmonary vessel is almost same as that of lymph node (arrows). However, VMI with 40 keV increased detectability and visibility of right interlobar lymph node.

Yue et al. (14) used VMI for the detection of inconspicuous osteoblastic metastases of the vertebra from lung cancer. They suggested that VMI at 70 keV could be the best for diagnosing inconspicuous vertebral metastases, which have a similar density and are therefore not distinguishable from normal vertebrae (Fig. 3) (14).

Fig. 3

Example of VMI for evaluation of bone metastasis.

Chest CT images from 62-year-old male with lung cancer and bone metastases. Osteoblastic lesion at T6 vertebral body suggestive of bone metastasis is more detectable on VMI with 70 keV than on conventional polychromatic images (arrows).

However, there was a correlation between attenuation and volume changes at different energy levels of VMI (15). VMI with high energy resulted in low attenuation and nodule volumes, while VMI with low energy resulted in higher attenuation and nodule volumes. This is probably caused by differences in the peripheral enhancement of nodules at different energy levels, making an enlargement or reduction, and leading to the over- or under-estimation of nodule volumes. Therefore, attention should be paid to the possibility of over- or under-estimation when attempting to measure nodule volume using VMI.

VNC

The DESCT technique allows for the acquisition of data at different kilovoltage settings and makes it possible to differentiate iodine from other materials. This technique enables the subtraction of the iodine content in contrast-enhanced DESCT, resulting in VNC. CT numbers of VNC were similar to true non-enhanced imaging (TNC) in a previous study (16). Therefore, VNC may easily detect calcifications or strongly attenuating nodes without additional TNC scanning, which results in reduced radiation exposure for the patient.

Evaluation of Mediastinal LNs

Although VNC may easily detect calcifications or strongly attenuating nodes without additional TNC scanning (Fig. 4), the quantification of calcium in VNC may have limitations. In a previous study, a moderate agreement was obtained between TNC and VNC in the evaluation of the CT attenuation of mediastinal LNs (intraclass correlation coefficient, 0.612) (17). In addition, there was an underestimation of high CT attenuation or calcification of the LNs in VNC compared to TNC. Another study by Chae et al. (16) also reported an underestimation of calcification in solitary pulmonary nodules (SPNs) or mediastinal LNs in VNC compared to TNC. These results could be due to partial subtraction of the calcium signal due to larger differences in photoelectric absorption compared to soft tissue, which results in a post-processing subtraction error.

Fig. 4

Example of virtual non-calcium reconstruction for evaluation of mediastinal lymph nodes (arrows).

Chest CT images of conventional polychromatic image, TNC, and VNC show calcified lymph node in subcarinal area of 42-year-old male. CT number of calcified lymph nodes in VNC (94 HU) was similar to that of TNC (89 HU). HU = Hounsfield unit, TNC = true non-enhanced imaging, VNC = virtual non-contrast or unenhanced imaging

Evaluation of Intratumoral Hemorrhage

Intratumoral hemorrhage or necrosis can develop during tumor treatment. It is challenging to evaluate tumor response in intratumoral hemorrhage or necrosis cases. Therefore, it is important to measure the real enhancement of the tumor. Intratumoral hemorrhage might lead to the overestimation of tumor diameters and may be regarded as an enhancing solid component, when only enhanced CT images are obtained. However, using VNC, intratumoral hemorrhage can be detected in patients with non-small cell lung cancer (NSCLC) treated with anti-angiogenic agents (18). Kim et al. (18) reported that intratumoral hemorrhage was detected in 14% (4 of 29) of all tumors in VNC (Fig. 5). Furthermore, DESCT provided information on the real enhancement of target lesions without obtaining TNC.

Fig. 5

Example of virtual non-calcium reconstruction for evaluation of intratumoral hemorrhage.

Chest CT images of enhanced conventional polychromatic image, TNC, and VNC from 52-year-old male with sarcoma derived from chronic empyema. Intratumoral hemorrhage was detected in TNC and VNC (arrows). VNC also provided information on real enhancement of target lesions (asterisk).

Virtual Non-Calcium Reconstruction for Diagnosing Vertebral Metastasis

Abdullayev et al. (19) evaluated the diagnostic accuracy and visualization of vertebral metastasis using virtual non-calcium reconstructions. They used a prototype image re-composition algorithm that allows for the reconstruction of virtual non-calcium images based on spectral base images (SBI). Virtual non-calcium reconstruction images effectively suppressed calcium in multi-level vertebra by replacing the Hounsfield unit (HU) of voxels containing calcium with a virtual HU value as similar as possible to the expected HU without the calcium contribution. They found that virtual non-calcium reconstruction improved the diagnostic performance of metastasis detection (Fig. 6).

Fig. 6

Example of VNC for diagnosing vertebral metastasis.

Chest CT images from 63-year-old male with lung cancer and bone metastases. Osteoblastic lesion at T8 vertebral body, which is suggestive of bone metastasis is more detectable on VNC than on conventional polychromatic image (arrows).

Evaluation of Adrenal Masses

In the evaluation of adrenal metastasis of lung cancer, VNC identified adrenal adenomas with 91% sensitivity and 100% specificity based on their typical imaging features (non-contrast attenuation < 10 HU) (Fig. 7) (20).

Fig. 7

Example of VNC in evaluation of adrenal masses.

CT images from 57-year-old female with lung cancer with adenoma in right adrenal gland (arrows).

A. In conventional polychromatic image, right adrenal adenoma shows mild contrast enhancement (left). CT number of right adrenal adenoma is 25.2 HU (right). B. In VNC, mild enhancement of right adrenal adenoma is not shown (left), and CT number is 3.5 HU (right).

Iodine Concentration Measurement

Several DESCT parameters can be derived from iodine concentration measurements, and spectral curves can be obtained in both the arterial phase (AP) and venous phase (VP) or only a single-phase (Table 2). The slope rate of the spectral HU curve (λHU), IC, and normalized iodine concentration (NIC) varied slightly from study to study (21), but the basic concept is similar.

Table 2

Several DESCT Parameters Derived from IC Measurements and Their Definitions

Parameters	Abbreviations (Unit)	Definition
Slope rate (or pitch) of spectral HU curve	λHU	Difference in CT values at 40 keV and 100 keV divided by 60 or at 40 keV and 120 keV divided by 80
Iodine concentration	IC (mg/mL)	Iodine content per unit volume (mL), measured at iodine-based material decomposition imaging
Normalized iodine concentration	NIC	Normalized to IC in aorta to minimize variation in patients, scanning times, and ICs: NIC = ICL/ICA

ICA = IC in aorta, ICL = IC in lesion

As DESCT parameters have been associated with IC measurement and reflected microvessel density and blood supply in previous studies (2223), IC measurements in dual-energy CT could serve as a biomarker of tumor vascularity and help to correctly measure the degree of pulmonary nodule enhancement (1624). Additionally, changes in iodine content could reflect a response to chemotherapy or radiation.

Malignant vs. Benign Lesions

Several studies showed significant differences in IC on DESCT parameters between malignant and benign lesions (Fig. 8). Lin et al. (21) compared DESCT parameters between SPNs of inflammation, malignancies, and tuberculosis. The λHU, IC, and NIC of inflammatory SPNs were significantly higher than those of malignant SPNs were, and those of malignant SPNs were significantly higher than those of tuberculosis were. Similarly, Xiao et al. (25) reported that IC and NIC in both the AP and VP of malignant SPNs were significantly higher than those of benign SPNs were. Wu et al. (26) showed NICs according to different spatial distributions could differentiate malignant SPNs from benign SPNs. Chen et al. (27) also showed IC, NIC, λHU, and VMI on 40 keV and 70 keV images at both AP and VP are more promising methods for distinguishing malignant from benign SPNs.

Fig. 8

Examples showing differences in IC of DESCT parameters between malignant and benign lesions.

CT images of enhanced conventional polychromatic, VMI at 40 keV and 100 keV, and iodine maps show different IC on DESCT parameters of (A) adenocarcinoma (λHU, 3; IC, 2.42 mg/mL; NIC; 0.229), (B) pulmonary tuberculosis (λHU, 0.217; IC, 0.17 mg/mL; NIC; 0.022), and (C) squamous cell carcinoma (λHU, 4.14; IC, 3.34 mg/mL; NIC; 0.337). DESCT = dual-energy spectral computed tomography, IC = iodine concentration, NIC = normalized iodine concentration, λHU = slope rate of spectral HU curve

However, several studies showed contradictory results to those discussed above. Results from Wang et al.'s study (28) showed significantly greater IC, λHU, and CT values at 40 keV in pneumonia than those in malignant tumors. Hou et al. (29) reported that inflammatory masses showed significantly higher λHU at AP and VP than malignant masses. Patients with inflammatory myofibroblastic tumors had significantly higher NIC and λHU at both AP and VP and IC differences between AP and VP than patients with lung cancer did (30). These results may be due to inappropriate angiogenesis resulting in abnormal vascular networks in lung cancer, which could cause tumor hypoxia and necrosis, leading to inhomogeneous enhancement on CT. However, further studies are needed to clarify these findings further.

There are also several studies about iodine content in DESCT related to LN metastases from lung cancers. LN metastases showed lower IC than benign LNs, which was statistically significant (20). λHU at both AP and VP were significantly higher in LN metastasis than in benign LNs, suggesting rapid washout of contrast media in metastatic LNs (31). Besides, several studies evaluated the correlation of iodine content with the diameters of LNs or lung cancer. Fehrenbach et al. (20) reported that enlarged LNs showed significantly lower IC and λHU than normal-sized nodes. Significant differences in IC, NIC, and λHU were observed between different LN diameters (normal: < 10 mm; intermediate: ≥ 10 mm to < 15 mm; enlarged: ≥ 15 mm). Aoki et al. (32) reported that the average iodine density was significantly lower in larger lung cancers. The authors believe that the development of hypoxia is related to the size of the tumor.

Differentiation of Tumors, Subtypes, Pathologic Grades, and Molecular Subcategories of Lung Cancer

There were significant differences in the DESCT parameters according to histologic subtypes and pathologic grades of lung cancer. Jia et al. (23) found that DESCT parameters with a combination of tumor markers were significantly different between adenocarcinoma, neuroendocrine tumors, and squamous cell carcinoma, and could be used to differentiate them. λHU at AP and IC in both AP and VP were significantly different among groups. In other studies, overall, iodine values were higher in adenocarcinoma than in squamous cell carcinoma (2028). Lin et al. (33) reported that NIC and λHU at both AP and VP in low-grade NSCLC were significantly higher than those in high-grade NSCLC were.

Several studies revealed a significant negative correlation between DESCT parameters and pathological grades of NSCLC. IC, λHU, and VMI at 40 keV showed a significant positive correlation with the level of vascular endothelial growth factor (VEGF) expression in NSCLC, proving the association between DESCT parameters and tumor angiogenesis (34). Li et al. (35) suggested that NIC might be a potential predictive quantitative parameter for the identification of epidermal growth factor receptor (EGFR) mutations in patients with adenocarcinoma. Their multivariate analysis revealed that smoking history and NIC were significant predictors of EGFR mutations in adenocarcinoma. The combination of these two significant predictive factors had moderate predictive value for identifying EGFR mutations in adenocarcinomas. Liu et al. (36) showed that there were significant differences in NICs between pure ground-glass nodules (GGN) and mixed GGN, and suggested that DESCT parameters could be an indicator of the blood supply status in GGN.

In addition, iodine content from DESCT could help to differentiate pulmonary metastases from different primary origins. Deniffel et al. (37) demonstrated significant differences in the IC and CT numbers in pulmonary metastases of renal cell carcinoma versus breast, colorectal, and head/neck carcinoma as well as metastases of colorectal carcinoma versus osteosarcoma, pancreato-biliary, and urinary tract carcinoma. They provided a reference range of the quantitative IC values derived from DESCT for these pulmonary metastases.

Iodine quantification with DESCT was also useful for differentiating low-risk thymomas from other thymic tumors. Yan et al. (38) demonstrated that the iodine content of low-risk thymomas measured in DESCT was significantly higher than that of high-risk thymomas, thymic carcinomas, and thymic lymphoma were.

Treatment Response Evaluation with/without Correlation with Positron Emission Tomography-CT

Several studies tried to validate the potential contribution of DESCT parameters in evaluating the therapeutic effects in lung cancers or mediastinal LNs. In a retrospective study by Baxa et al. (39), the mean values of IC in both AP and VP before and after chemotherapy increased in the non-responding LNs and decreased in the LNs with a response. Liu et al. (40) evaluated therapeutic effects after radiofrequency ablation (RFA) of lung tumors using DESCT parameters. The iodine content significantly decreased after RFA, reflecting the metabolic state of the tumors. Izaaryene et al. (41) reported that iodine content predicted early recurrence of primary or secondary lung tumors after RFA and suggested a threshold between 20 HU and 35 HU. Fehrenbach et al. (42) also demonstrated that DESCT parameters of NSCLC after chemoradiotherapy might help in predicting recurrence. In their study, NSCLC with progressive disease (PD) showed significantly higher IC than tumors in patients with stable disease (SD) or partial response. Patients with PD during follow-up (FU) had significantly higher IC on the initial DESCT scan than those with SD during FU. The IC difference (IC at hotspot analysis - IC) and NIC difference (NIC at hotspot analysis - NIC) was significantly different between PD, PD during FU, and SD during FU.

The correlation between DESCT parameters and metabolic uptake in 18F-fluorodeoxyglucose positron emission tomography (PET-CT) and association with tumor recurrence were also evaluated in several studies. Aoki et al. (4344) found strong correlations between IC and the maximum standardized uptake value (SUVmax) on PET-CT with local recurrence in NSCLC treated with stereotactic body radiotherapy (SBRT). Tumors with a lower IC and higher SUVmax showed significantly higher local recurrence rates, demonstrating an association of radioresistance with low tumor blood volume and a probable association with hypoxia. According to Ren et al. (45), the strong association between DESCT parameters and PET-CT was also found in primary or metastatic lung tumors, and both pre- and post-treatment with radiotherapy or chemoradiotherapy.

Parenchymal Perfusion Defects due to Central Lung Cancers or Pulmonary Thromboembolism

Pulmonary perfusion defects induced by central lung cancer could be easily detected by IC (46). Perfusion defects caused by pulmonary thromboembolism, which can develop with lung cancer or in the course of lung cancer treatment could be identified and quantified by a significant decrease in IC in the affected areas compared to the surrounding lung tissue (Fig. 9) (20).

Fig. 9

Example showing differences in IC of pulmonary perfusion defects induced by central lung cancer.

A. Enhanced chest CT axial image shows 7 cm well-enhanced mass proven to be adenocarcinoma from 68-year-old male. B. Coronal image shows total obstruction of pulmonary artery of RUL (arrow). C. Axial image with lung window setting shows patchy consolidation in RUL, which is suggestive of lung infarction (arrow). D. IC map showing decreased IC in right middle lobe (0.07 and 0.03 mg/mL), which is suggestive of decreased lung perfusion, compared to that of contralateral lung (1.01 mg/mL). RUL = right upper lobe

Effective Atomic Number (Zeff map)

Zeff is a quantitative index that represents the composite atom for a compound or mixture of various materials, which can be calculated from DESCT data with a small error rate (4.1% ± 0.3%) (47). Regardless of X-ray energy, the CT number of water is zero, and the Zeff of water is about 7.4–7.5 (2).

As the clinical significance of Zeff is unclear, Zeff has not been well studied in the field of thoracic oncology. Only a few studies on this topic have been published. Significantly greater Zeff was measured in benign thyroid nodules than in papillary carcinomas (48), and higher Zeff was exhibited in soft-tissue sarcomas than in normal tissues (49). For lung tumors, a lower minimum Zeff and normalized mean Zeff statistically correlated with malignant lung tumors (47). Zeff at both AP and VP were significantly different between squamous cell cancer, adenocarcinoma, and neuroendocrine tumors (23).

CONCLUSION

The technical aspects of DESCT have rapidly developed in recent years, and much research has been done on the application of DESCT in thoracic oncology. However, further research is still required. The DESCT parameter values are not uniform across studies, and Zeff has not been well studied in relation to the thoracic oncology field. If the potential advantages of the DESCT technique can be used in the field of thoracic oncology, we believe that significant advances will be made in appropriate early diagnoses, assessing tumor response, and prognostic assessment.